FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220738064> ?p ?o ?g. }

• W4220738064 endingPage "307.e8" @default.
• W4220738064 startingPage "307.e1" @default.
• W4220738064 abstract "Induction therapy with a triplet regimen, followed by high-dose therapy and autologous hematopoietic stem cell transplantation (auto-HCT), is the standard of care for newly diagnosed, transplant-eligible patients with multiple myeloma (MM). Bortezomib-dexamethasone with cyclophosphamide (VCD) or lenalidomide (VRD) are the most used induction regimens. However, previous studies comparing VCD and VRD showed disparate results. The goal of this retrospective study was to compare the real-world results of VCD and VRD in transplant-eligible MM patients outside of a clinical trial. We identified 322 patients who received VRD or VCD induction before auto-HCT at our institution. All patients received melphalan conditioning and single-agent lenalidomide maintenance therapy. Overall, 114 patients received VCD, and 208 received VRD. The median age at auto-HCT was 61.9 years (range 33.9-79.6), with 35.4% (114/322) of the cohort being 65 years of age or older. The overall response rate was 99.7% after auto-HCT, with a significantly lower complete remission rate as the final response in the VCD compared to the VRD group (34% versus 53%; P = .001). However, there was no significant difference between the best response rate of very good partial response (VGPR) or better in the VCD compared to the VRD group (92% versus 85%; P = .078). The median duration of ≥VGPR was 50.0 months (95% confidence interval [CI], 42.0-69.1) for both cohorts, and there was no difference between VCD and VRD (P = .769; hazard ratio, 0.95; 95% CI, 0.69-1.31). Median follow-up of survivors was 73 months. There was no difference in the relapse rate between VCD and VRD (P = .749). Median progression-free survival (PFS) was 48.7 months in the VCD and 44.6 months in the VRD group (P = .858). Median overall survival (OS) was 103.8 months with VCD and 101.7 months with VRD (P = .891). At 5 years, the PFS and OS were 38.1% and 76.9% for the VCD group, respectively, and 40.7% and 74.6% for the VRD group, respectively. On multivariate analysis for OS in the entire cohort, Revised International Staging System I and post-auto-HCT best response of stringent complete response (sCR)/CR emerged as significant predictors of superior OS. There was no impact of the type of induction regimen on the OS in the multivariate analysis. Induction therapy with VCD compared to VRD was associated with a lower CR rate, but there was no difference in PFS or OS between the 2 regimens." @default.
• W4220738064 created "2022-04-03" @default.
• W4220738064 creator A5008366988 @default.
• W4220738064 creator A5008785159 @default.
• W4220738064 creator A5015342719 @default.
• W4220738064 creator A5017057018 @default.
• W4220738064 creator A5018938811 @default.
• W4220738064 creator A5029059663 @default.
• W4220738064 creator A5032868562 @default.
• W4220738064 creator A5037077714 @default.
• W4220738064 creator A5038235561 @default.
• W4220738064 creator A5038619722 @default.
• W4220738064 creator A5048362577 @default.
• W4220738064 creator A5048913229 @default.
• W4220738064 creator A5050962913 @default.
• W4220738064 creator A5055879561 @default.
• W4220738064 creator A5055885795 @default.
• W4220738064 creator A5055929208 @default.
• W4220738064 creator A5059394802 @default.
• W4220738064 creator A5060313982 @default.
• W4220738064 creator A5066894053 @default.
• W4220738064 creator A5068834306 @default.
• W4220738064 creator A5069460930 @default.
• W4220738064 creator A5071516639 @default.
• W4220738064 date "2022-06-01" @default.
• W4220738064 modified "2023-09-23" @default.
• W4220738064 title "Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation" @default.
• W4220738064 cites W1520916227 @default.
• W4220738064 cites W1804942062 @default.
• W4220738064 cites W1963774766 @default.
• W4220738064 cites W1980168719 @default.
• W4220738064 cites W2003734726 @default.
• W4220738064 cites W2013370486 @default.
• W4220738064 cites W2013806710 @default.
• W4220738064 cites W2015003025 @default.
• W4220738064 cites W2102591890 @default.
• W4220738064 cites W2125721471 @default.
• W4220738064 cites W2128084036 @default.
• W4220738064 cites W2128515279 @default.
• W4220738064 cites W2141247841 @default.
• W4220738064 cites W2318069817 @default.
• W4220738064 cites W2486629951 @default.
• W4220738064 cites W2511151602 @default.
• W4220738064 cites W2604776612 @default.
• W4220738064 cites W2737964630 @default.
• W4220738064 cites W2746456353 @default.
• W4220738064 cites W2786804053 @default.
• W4220738064 cites W2799981419 @default.
• W4220738064 cites W2955929550 @default.
• W4220738064 cites W3096639092 @default.
• W4220738064 cites W3213320033 @default.
• W4220738064 doi "https://doi.org/10.1016/j.jtct.2022.03.020" @default.
• W4220738064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35331973" @default.
• W4220738064 hasPublicationYear "2022" @default.
• W4220738064 type Work @default.
• W4220738064 citedByCount "1" @default.
• W4220738064 countsByYear W42207380642022 @default.
• W4220738064 crossrefType "journal-article" @default.
• W4220738064 hasAuthorship W4220738064A5008366988 @default.
• W4220738064 hasAuthorship W4220738064A5008785159 @default.
• W4220738064 hasAuthorship W4220738064A5015342719 @default.
• W4220738064 hasAuthorship W4220738064A5017057018 @default.
• W4220738064 hasAuthorship W4220738064A5018938811 @default.
• W4220738064 hasAuthorship W4220738064A5029059663 @default.
• W4220738064 hasAuthorship W4220738064A5032868562 @default.
• W4220738064 hasAuthorship W4220738064A5037077714 @default.
• W4220738064 hasAuthorship W4220738064A5038235561 @default.
• W4220738064 hasAuthorship W4220738064A5038619722 @default.
• W4220738064 hasAuthorship W4220738064A5048362577 @default.
• W4220738064 hasAuthorship W4220738064A5048913229 @default.
• W4220738064 hasAuthorship W4220738064A5050962913 @default.
• W4220738064 hasAuthorship W4220738064A5055879561 @default.
• W4220738064 hasAuthorship W4220738064A5055885795 @default.
• W4220738064 hasAuthorship W4220738064A5055929208 @default.
• W4220738064 hasAuthorship W4220738064A5059394802 @default.
• W4220738064 hasAuthorship W4220738064A5060313982 @default.
• W4220738064 hasAuthorship W4220738064A5066894053 @default.
• W4220738064 hasAuthorship W4220738064A5068834306 @default.
• W4220738064 hasAuthorship W4220738064A5069460930 @default.
• W4220738064 hasAuthorship W4220738064A5071516639 @default.
• W4220738064 hasBestOaLocation W42207380641 @default.
• W4220738064 hasConcept C126322002 @default.
• W4220738064 hasConcept C141071460 @default.
• W4220738064 hasConcept C207103383 @default.
• W4220738064 hasConcept C2776063141 @default.
• W4220738064 hasConcept C2776364478 @default.
• W4220738064 hasConcept C2777408962 @default.
• W4220738064 hasConcept C2777478702 @default.
• W4220738064 hasConcept C2778684742 @default.
• W4220738064 hasConcept C2779050716 @default.
• W4220738064 hasConcept C2911091166 @default.
• W4220738064 hasConcept C44249647 @default.
• W4220738064 hasConcept C71924100 @default.
• W4220738064 hasConceptScore W4220738064C126322002 @default.
• W4220738064 hasConceptScore W4220738064C141071460 @default.
• W4220738064 hasConceptScore W4220738064C207103383 @default.
• W4220738064 hasConceptScore W4220738064C2776063141 @default.
• W4220738064 hasConceptScore W4220738064C2776364478 @default.

• next